Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
Safety, efficacy, and patient-reported outcomes (PROs) with vimseltinib in patients (pts) with tenosynovial giant cell tumor (TGCT) who received prior antiecolony-stimulating factor 1 (CSF1) therapy: Ongoing phase II study
Safety, efficacy, and patient-reported outcomes (PROs) with vimseltinib in patients (pts) with tenosynovial giant cell tumor (TGCT) who received prior antiecolony-stimulating factor 1 (CSF1) therapy: Ongoing phase II study D'Amato, G., Wagner, A. J., Ganjoo, K. N., Stacchiotti, S., Gelderblom, H., Ryan, C. W., Palmerini, E., Ravi, V., Saleh, R., Le Cesne, A., Bernthal, N. M., van de Sande, M., Narasimhan, S., Harrow, B., Saunders, A., Ruiz-Soto, R., Sherman, M. L., Tap, W. D. ELSEVIER. 2024: S1054View details for DOI 10.1016/j.annonc.2024.08.1861
View details for Web of Science ID 001326612902390